Background Phosphate binders are used to reduce positive phosphate balance and to lower
serum phosphate levels for people with chronic kidney disease (CKD) with the aim to …

Hyperphosphatemia is a common complication in patients with chronic kidney disease
(CKD), particularly in those requiring renal replacement therapy. The importance of …

Phosphate binders include calcium acetate or carbonate, sevelamer hydrochloride or
carbonate, magnesium and lanthanum carbonate, and aluminum carbonate or hydroxide …

BACKGROUND: Phosphate binders are widely used to control serum phosphorus levels in
patients with chronic kidney disease (CKD). We analyzed the effects of phosphate binders …

Mineral and bone disorders (MBD) are common in patients with chronic kidney disease
(CKD), contributing to significant morbidity and mortality. For several decades, the first-line …

Prevention and correction of hyperphosphatemia is a major goal of chronic kidney disease–
mineral and bone disorder (CKD–MBD) management, achievable through avoidance of a …

Introduction Hyperphosphatemia is an inevitable complication for patients undergoing
dialysis, as is the resulting need for treatment with phosphate binders. Currently, various …

Hyperphosphatemia is an inevitable consequence of end-stage chronic kidney disease and
is present in the majority of dialysis patients. Hyperphosphatemia is observationally and …

Introduction: Disturbances of the bone and mineral metabolism are a common complication
of chronic kidney disease (CKD); these disturbances are known as CKD–mineral bone …

The skeletal disorders associated with renal insufficiency result from alterations in calcium,
phosphorus, and vitamin D metabolism. Each requires intervention to prevent and control …